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Abstract Chemically modified tetracyclines |CMT-3 (IC5 0 
~ 6 - 1 3 uM = ~ 2.5-5 jig/ml) and CMT-8 (IC5 0 ~ 2 6 uM = 
10 (ig/nil), but not CMT-1, -2 or -5], which lack anti-microbial 
activity, inhibited nitrite production in LPS-stimulated macro-
phages. Unlike competitive inhibitors of L-arginine which 
inhibited the specific activity of inducible nitric oxide synthase 
(iNOS) in cell-free extracts, CMTs exerted no such direct effect 
on the enzyme. CMTs could, however, be shown to inhibit both 
iNOS mRNA accumulation and protein expression in LPS-
stimulated cells. Tetracyclines (doxycycline and CMT-3) unlike 
hydrocortisone had no significant effect on murine macrophages 
transfected with iNOS promoter (tagged to a luciferase reporter 
gene) in the presence of LPS. However, doxycycline and CMT-3 
augmented iNOS mRNA degradation, in LPS-stimulated murine 
macrophages. These studies show a novel mechanism of action of 
tetracyclines which harbours properties to increase iNOS mRNA 
degradation and decrease iNOS protein expression and nitric 
oxide production in macrophages. This property of tetracyclines 
may have beneficial effects in the treatment of various diseases 
where excess nitric oxide has been implicated in the pathophys-
iology of these diseases. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Nitric oxide (NO), first identified as an endothelium-derived 
relaxation factor, is now recognized to regulate the functions 
of many mammalian cells and tissues [1]. N O is produced by 
the ubiquitous enzyme, nitric oxide synthase (NOS). The over-
expression of inducible N O S (iNOS) in a variety of inflamma-
tory tissues had led many to conclude that the modulat ion of 
N O synthesis and action could represent a new approach to 
treatment of inflammatory and autoimmune diseases [2,3], 
including osteoarthritis (OA) [4] and rheumatoid arthritis 
(RA) [5]. 
*Corresponding author. Fax: (1) (212) 598 6168. 
Abbreviations: CMT, chemically modified tetracycline; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase; LPS, lipopolysaccharide; 
MMP, matrix metalloprotease; NO, nitric oxide; NOS, nitric oxide 
synthase; iNOS, inducible nitric oxide synthase; OA, osteoarthritis; 
RA, rheumatoid arthritis 
Various studies have shown that among the tetracycline 
group of broad-spectrum antibiotics, doxycycline and mino-
cycline exert biological effects independent of their anti-micro-
bial activity [6-9]. Such effects include inhibition of activity of 
matrix metalloproteases (MMPs) , including collagenase 
(MMP-1), gelatinase (MMP-2) and stromelysin (MMP-3), 
and prevention of pathogenic tissue destruction [6]. Recent 
studies have also indicated that tetracyclines and inhibitors 
of M M P s block tumor progression [10], bone resorption [11] 
and angiogenesis [12]. In view of these diverse effects of tetra-
cyclines, we have also observed that doxycycline and minocy-
cline inhibit iNOS expression in murine macrophages [13]. 
The present study shows that : (a) some chemically modified 
tetracyclines (CMT-3 and CMT-8, but not CMT-1 or CMT-5) 
share the ability to inhibit iNOS expression in a similar fash-
ion as observed with doxycycline and minocycline; (b) CMT-3 
and doxycycline augment iNOS m R N A degradation and have 
no significant influence on iNOS gene transcription. 
2. Materials and methods 
Murine macrophage cells (RAW 264.7) were obtained from ATCC 
(Rockville, MD, USA). An anti-murine iNOS antibody was obtained 
from Transduction Laboratories (Lexington, KY, USA). Doxycycline, 
minocycline, hydrocortisone, ./V-acetyl imidazole (NA1), and lipopoly-
saccharide (LPS) were obtained from Sigma (St. Louis, MO, USA). 
The CMTs (designated as CMT-1, -2, -3, -5 and -8) were a generous 
gift from CollaGenex (Newtown, PA, USA). 
Equal amounts of protein (25-50 u.g) estimated by BCA reagent 
(Pierce, Rockford, IL, USA) were loaded onto SDS-PAGE gels and 
stained to verify the concentrations of various protein fractions by 
examining the intensities of the protein bands on the gels. Western 
blot analysis was carried out from the same cell extracts. The Western 
blot was probed with a specific anti-iNOS murine mAb as specified by 
Transduction Laboratories. Membranes with bound antibodies (e.g., 
iNOS) were stripped by submersion in stripping buffer (100 mM 
2-mercaptoefhanol, 2% SDS, 62.5 mM Tris-HCl, pH 6.7) and incu-
bating at 50°C for 30 min with occasional agitation. Membranes were 
then washed twice for 10 min at RT using large volumes of wash 
buffer. The same blot was also probed with an anti-actin antibody 
generously provided by Dr. James L. Lessard (Children's Hospital 
Medical Center, Cincinnati, OH, USA) using the standard protocol. 
Blots were developed using the ECL Western blot system (Amersham, 
Arlington Heights, IL, USA). Quantitation of the bands was per-
formed using a densitometer from Molecular Dynamics (Sunnyville, 
CA, USA). 
Total RNA was isolated using TRI Reagent (MRC, Cincinnati, 
OH, USA). Northern blot analysis was carried out as described earlier 
[14,15]. Briefly, 20 ug of RNA was subjected to electrophoresis in 1% 
agarose formaldehyde gel, and then transferred via capillary action 
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onto a nylon membrane (Zeta Probe, Bio-Rad Laboratories, Melville, 
NY, USA). The membrane was hybridized with [32P]dCTP-labelled 
iNOS cDNA (4 kb Smal fragment), a kind gift from Dr. James Cun-
ningham (Harvard Medical School, Boston, MA, USA). After hybrid-
ization, the blot was exposed to Kodak X-ray film (Kodak, Rochester, 
NY, USA) for 24-48 h with intensifying screens at -70°C. The 
GAPDH probe was purchased from ClonTech (Palo Alto, CA, 
USA) and probed as described above. Quantitation of the intensity 
of the iNOS and GAPDH bands was performed using a Personal 
Densitometer SI (Molecular Dynamics). 
Specific activity of iNOS was determined in cell-free extracts by 
monitoring the conversion of L-[3H]arginine to L-[3H]citrulline as de-
scribed [15,16], RAW 264.7 cells were induced with LPS (100 ng/ml) 
in the presence and absence of minocycline, CMTs or hydrocortisone 
for 14-20 h. Following induction, the cells were pelleted at 4°C and 
resuspended in Tris buffer (10 mM, pH 7.4) containing 10 pg/ml each 
chymostatin, antipain, leupeptin and pepstatin, 1 mM DTT and 1 mM 
PMSF [15]. Cells were lysed in a Polytron PT1200 homogenizer (Kin-
ematica, Switzerland) after 3 cycles of rapid freeze-thawing. The lysate 
was centrifuged at 16000 rpm for 60 min at 4°C, and the supernatants 
were used as cell-free extracts. The protein was measured by BCA 
assay reagent using BSA as standard [17]. The reaction mixture for 
iNOS assay consists of Tris 50 mM (pH 7.8); BSA 1 mg/ml; DTT 
1 mM; CaCl2 2 mM; FAD 10 pM; BH4 10 pM; L-arginine 30 uM; 
NADPH 1 mM. The reaction mixture was spiked with 1 pi (250 nM) 
of L-[3H]arginine (Du Pont NEN, Boston, USA, MA) (1 mCi/ 
ml = 37.0 MBq/ml). After 20 min the assays were terminated by heat-
ing the reaction mixture at 90°C for 5 min; 10 pi ( = 100000 cpm) of 
the supernatant was spotted on activated Avicel TLC plates (Anal-
tech, Newark, DE, USA). The TLC plates were developed in a solvent 
system consisting of ethanol/water/ammonia (80:16:4). Quantitation 
of the spot for L-[3H]citrulline was performed by a Bioscan System 
200 Imaging Scanner. 
RNA stability analysis was carried out as previously described [18]. 
Briefly, cells were stimulated with 100 ng/ml of LPS (± tetracycline) 
followed by addition of actinomycin D (5 pg/ml) 4 h post-stimulation. 
Total RNA was prepared at different time periods and analyzed by 
Northern blot analysis as described above. The data are represented 
as percentage of iNOS mRNA degraded after normalizing the values 
with GAPDH. 
RAW 264.7 cells were transfected with the 1.7 kb murine iNOS 
promoter linked to a luciferase reporter gene [19] using the DEAE-
dextran method as previously described [20]; 10 pg of the plasmid 
DNA was added to 107 cells in 1.0 ml of DMEM (without serum) 
containing DEAE-dextran (250 pg/ml) and 50 mM Tris (pH 7.4). The 
suspension was further incubated at 37°C for 60 min followed by a 1.0 
min shock with 10% DMSO at room temperature. These cells were 
incubated for 45 min with the respective drugs and stimulated with 
100 ng/ml LPS 24 h post-transfection. The cells were finally harvested 
24 h after LPS stimulation and assayed for luciferase activity as de-
scribed by the manufacturer's instructions (Promega, Madison, WI, 
USA). 
3. Results and discussion 
Our recent studies show that doxycycline and minocycline 
inhibit iNOS expression at the level of iNOS mRNA accumu-
lation in murine macrophages stimulated with LPS [13]. In 
view of these observations, we examined if chemically modi-
fied tetracyclines as shown in Fig. 1 and which lack anti-mi-
crobial activity as previously reported [21], could also modu-
late iNOS expression. We therefore compared the effects of 
CMTs and minocycline on nitrite accumulation in LPS-stimu-
lated murine macrophages as shown in Fig. 2. CMT-3 > 
CMT-8 (but not CMT-1, -2, or -5) inhibited nitrite accumu-
lation in a dose-dependent manner. The IC50 level of CMT-3 
was < 2.5 pg/ml ( < 6 uM) while that of CMT-8 was ~ 10 pg/ 
ml (~26 uM). CMT-2 and CMT-5 at concentrations of 10 
pg/ml did not show a significant effect on nitrite accumulation 
(Fig. 2), whereas a marginal effect (inhibition) was seen with 
minocycline and CMT-1 at similar concentrations. These ex-
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Fig. 1. Structures of doxycycline, minocycline and various chemi-
cally modified tetracyclines used in this study (provided by Colla-
genex, Inc.). 
periments demonstrate that CMT-3 is more effective in its 
ability to inhibit nitrite accumulation than doxycycline, min-
ocycline [13], and other CMTs tested in these studies. 
We further examined the effects of CMT-3 and CMT-8 on 
the enzyme activity of iNOS. Cells were stimulated with LPS 
in the presence of equal amounts of CMT-3 or -8 for 16 h. 
The medium was assayed for nitrite and iNOS enzyme in cell 
extracts in an L-arginine-to-L-citrulline conversion assay. As 
expected, CMT-3 and hydrocortisone inhibited nitrite accu-
mulation significantly more than CMT-8. These data were 
substantiated by a significant decrease in specific enzyme ac-
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Fig. 2. Effect of CMTs on nitrite accumulation in murine macrophages stimulated with LPS. Murine macrophages (RAW 264.7 cells) were 
stimulated with LPS (100 ng/ml) in the presence of 10 |xg/ml minocycline (MINO) and various concentrations of CMTs in triplicate for 48 h. 
The levels of nitrite were estimated by the modified Griess method [31]. Data are expressed as |a,M nitrite accumulated of triplicate determinants 
(n = 3). Statistics were derived using unpaired Student's /-test. Data represent 1 of 3 similar experiments. 
tivity of iNOS in the intact cells, as shown in Table 1. These 
experiments demonstrated that the decrease in nitrite accumu-
lation by the CMTs could be partially to the decrease in iNOS 
enzyme activity within the cells. 
Various investigators have shown that tetracyclines inhibit 
collagenase activity via direct effects on the enzyme [22-24]. 
Another mechanism proposed for this phenomenon is that 
procollagenase is reduced to inactive fragments upon activa-
tion in the presence of doxycycline [23]. We have recently 
shown that acetylating agents such as aspirin and N-acetyl 
imidazole [15], as well as competitive inhibitors of L-arginine 
(NMA), inhibit iNOS catalytic activity in cell-free extracts. In 
view of these observations, we examined the direct effect of 
CMTs on the ability of iNOS to convert radiolabelled L-
[3H]arginine to L-citrulline in cell-free extracts in vitro. 
RAW 264.7 cells were stimulated with LPS for 16 h and 
cell-free extracts were made. Separate aliquots of equal 
amounts of enzyme were preincubated with various concen-
trations of CMTs (6-24 uM), NMA (200 uM) or NAI (1 mM) 
for 20 min before the enzyme reaction was initiated after the 
addition of co-factors. As expected, NMA and NAI showed 
75 and 45% inhibition of iNOS enzyme activity, respectively, 
but there was no significant effect ( < 5% inhibition) by the 
CMTs (data not shown). These experiments demonstrate that 
the action of these CMTs, like the doxycycline and minocy-
cline [13], seems to be distinct from those reported for MMPs 
such as procollagenase at similar concentrations [22,23,25]. In 
view of the above observation and our previous experiments 
which indicate that iNOS protein is decreased by doxycycline 
and minocycline [13], we tested the effects of CMT-3 and —8 
at various concentrations on iNOS protein expression. RAW 
264.7 cells were stimulated with LPS in the presence and ab-
sence of CMTs for 16 h; cell-free extracts were prepared and 
examined for iNOS expression by Western blot analysis. Fig. 
3 shows that, like minocycline [13], CMT-3 > CMT-8 inhib-
ited 133 kDa iNOS expression. The effect of CMT-3 at 2.5 u.g/ 
ml was similar to that observed with 20 u.g/ml of minocycline. 
The inhibition in the accumulation of nitrite in the same ex-
periment was substantiated with the data shown in the West-
ern blot analysis. Hydrocortisone, as expected, inhibited iNOS 
expression as previously reported [15]. Furthermore, there was 
no significant difference in the constitutively expressed pro-
Table 
Effect of CMTs on the specific activity of iNOS 
Modulating agent Nitrite released 
uM % inhibition 
Specific activity 
pmol/min per mg protein % inhibition 
Control (uninduced) 
LPS induced 
CMT-3 (10 |ig/ml) 
CMT-8 (10 ng/ml) 
Hydrocortisone (10 uM) 
<0.1 
22.9 
12.2 
17.0 
11.8 
N/A 
N/A 
47 
26 
49 
< 5 
90.8 
37.6 
79.2 
51.5 
N/A 
N/A 
58.6 
12.7 
43.3 
Murine macrophage cells were stimulated with 100 ng/ml of LPS in the presence of CMTs or hydrocortisone for 16 h. The nitrite accumulated in 
the medium was examined and the enzyme activity assayed from cell-free extracts. Percent inhibition of nitrite/specific activity was calculated after 
comparing the values with LPS-stimulated cells. 10 ug/ml of CMT-3/8 was equivalent to 27 uM. The data represent one of two similar experiments. 
N/A, not applicable. 
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Fig. 3. Western blot analysis of iNOS in RAW 264.7 cells exposed to minocycline, CMTs and hydrocortisone in the presence of LPS for 16 h. 
Mino: represents minocycline (20 ug/ml equivalent to 40 u,M). Hydro: represents hydrocortisone (10 uM equivalent to 3.4 ug/ml). CMT-3 (2.5, 
5 and 10 |tg/ml equivalent to 27, 13 and 6 |xM, respectively) and CMT-8 (5 and 10 (xg/ml equivalent to 27 and 13 |xM, respectively). Cell-free 
extracts were prepared and aliquots were blotted and probed with a specific a-iNOS mAb. The percent inhibition of iNOS expression was com-
pared to LPS-stimulated cells, as determined by a densitometer scan, after normalizing the values with P-actin in the same blot. The upper pan-
el shows the representative nitrite values in this particular experiment. The data represent 1 of 2 similar experiments. 
teins (such as P-actin) when the same blot was reprobed with 
anti-P-actin antibodies (Fig. 3). These experiments indicate 
that the decrease in NOS activity could be due to a decrease 
in the expression of iNOS protein. 
Based on our previous studies with doxycycline and mino-
cycline, we tested the ability of CMTs to inhibit iNOS mRNA 
accumulation in RAW 264.7 cells stimulated with LPS for 16 
h. Fig. 4 shows a dose-dependent inhibition of iNOS mRNA 
accumulation by CMT-3. CMT-8 at 5 and 10 ug/ml showed a 
significant decrease in iNOS mRNA accumulation as com-
pared to LPS-stimulated cells, whereas CMT-1 at 10 (j.g/ml 
showed no significant effect when the values were normalized 
with the respective GAPDH signals. The effect of hydrocorti-
sone in this particular experiment was relatively less when the 
Fig. 4. Northern blot analysis of iNOS mRNA expression in RAW 264.7 cells stimulated with LPS in the presence of CMTs at 16 h. Total 
RNA was extracted and analyzed by Northern blot using a-iNOS and a-GAPDH probes. The iNOS/GAPDH signal was quantitated using a 
phosphoimager. The percent inhibition of iNOS mRNA expression was normalized with the GAPDH signal and compared with the values of 
the LPS-stimulated cells. Data represent 1 of 2 similar experiments. 
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Fig. 5. Effect of doxycycline and CMT-3 on iNOS mRNA stability. 
RAW 264.7 cells were stimulated with 100 ng/ml of LPS in the 
presence or absence of doxycycline (40 ng/ml) or CMT-3 (10 |ig/ml) 
for 4 h, followed by addition of actinomycin D (5.0 |xg/ml). The 
cells were then harvested at different time intervals (0-120 min) and 
analyzed for iNOS mRNA accumulation as described in Section 2. 
The values for iNOS mRNA accumulation were normalized with 
GAPDH for equal loading. The percent inhibition of iNOS mRNA 
in tetracycline-treated cells was calculated against LPS-stimulated 
cells alone using a densitometer. 
mRNA was in its steady state [15]. The effects of hydrocorti-
sone have been seen to be more significant when the iNOS 
mRNA is examined at 4 h post-stimulation where it blocks 
N F - K B activation and iNOS transcription. 
To examine the mechanism by which tetracyclines (doxycy-
cline and CMT-3) decrease iNOS RNA accumulation, we 
evaluated the effects of these compounds on iNOS transcrip-
tion and mRNA stability. Murine macrophages were trans-
fected with a full-length iNOS promoter (tagged to a lucifer-
ase reporter gene) and stimulated with LPS in the presence 
and absence of doxycycline, CMT-3 and hydrocortisone. 
Stimulation of these cells with LPS alone increased the rela-
tive light units of luciferase activity from 0.22 to 35.0 which 
was designated as 100%. In a parallel experiment, 10 uM of 
hydrocortisone showed 88% inhibition of luciferase activity. 
Doxycycline at 20 and 40 ug/ml (41 and 82 uM, respectively) 
and CMT-3 at 10 ug/ml (25 uM) which markedly inhibited 
nitrite accumulation had no significant effect on the luciferase 
activity in the presence of LPS (data not shown). These ex-
periments indicate that, unlike hydrocortisone, tetracyclines 
have no significant effect on iNOS transcription when stimu-
lated with LPS. 
We next examined the effects of tetracyclines on iNOS 
mRNA stability. Murine macrophage cells were stimulated 
with LPS (± doxycycline or CMT-3) for 4 h followed by in-
cubation with actinomycin D. Total RNA was extracted at 
different time intervals after the addition of actinomycin D 
and examined for iNOS mRNA expression by Northern 
blot analysis. Fig. 5 shows that both CMT-3 > doxycycline 
augments iNOS mRNA instability when compared to cells 
incubated with LPS alone. Previous studies have shown that 
murine iNOS mRNA is modulated at post-transcriptional lev-
els, by TGF|3 [18], Fe(3+) [26] and cycloheximide [27]. 
In summary, these experiments demonstrate that CMT-3 
and -8 (both devoid of anti-microbial activity), like doxycy-
cline and minocycline, can inhibit iNOS activity in murine 
macrophages. CMT-3 > CMT-8 at concentrations used in 
this study have been reported to inhibit collagenase activity, 
whereas CMT-5 showed no appreciable effect [28]. Further-
more, CMT-3 > CMT-8 were found to be more potent in 
their ability to inhibit iNOS expression when compared to 
effects of doxycycline and minocycline as previously reported 
[13]. This study also demonstrates that the mechanism of ac-
tion of at least two tetracyclines (doxycycline and CMT-3) is 
similar: they render the iNOS mRNA susceptible to degrada-
tion and thereby decrease iNOS expression and nitric oxide 
production. These experiments support the previous hypoth-
esis that tetracyclines, independent of their anti-microbial ac-
tivity, exert pleiotropic functions including inhibition of 
MMPs, NOS expression, protection against peroxynitrite-de-
pendent injury, angiogenesis, tumor progression, bone resorp-
tion and inflammation [10,12,29,30]. We hypothesize that the 
multifunctional properties of tetracyclines may be partly at-
tributed to their ability to target another pleiotropic signalling 
molecule, NO, that has been shown to exert similar effects on 
many of the pathological conditions and manifestations. 
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